Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5268546
Max Phase: Preclinical
Molecular Formula: C57H61F3N10O5S2
Molecular Weight: 1087.31
Associated Items:
ID: ALA5268546
Max Phase: Preclinical
Molecular Formula: C57H61F3N10O5S2
Molecular Weight: 1087.31
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCN2CCN(c3ccc(C#Cc4ccc(N5C(=S)N(c6ccc(C#N)c(C(F)(F)F)c6)C(=O)C5(C)C)cc4)cn3)CC2)C(C)(C)C)cc1
Standard InChI: InChI=1S/C57H61F3N10O5S2/c1-35(39-15-17-40(18-16-39)49-36(2)63-34-77-49)64-51(73)46-30-44(71)33-68(46)52(74)50(55(3,4)5)65-48(72)9-8-24-66-25-27-67(28-26-66)47-23-14-38(32-62-47)11-10-37-12-20-42(21-13-37)70-54(76)69(53(75)56(70,6)7)43-22-19-41(31-61)45(29-43)57(58,59)60/h12-23,29,32,34-35,44,46,50,71H,8-9,24-28,30,33H2,1-7H3,(H,64,73)(H,65,72)/t35-,44+,46-,50+/m0/s1
Standard InChI Key: UESVUNITXHBXAZ-RIZNWJGOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1087.31 | Molecular Weight (Monoisotopic): 1086.4220 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Han X, Wang C, Qin C, Xiang W, Fernandez-Salas E, Yang CY, Wang M, Zhao L, Xu T, Chinnaswamy K, Delproposto J, Stuckey J, Wang S.. (2019) Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer., 62 (2): [PMID:30629437] [10.1021/acs.jmedchem.8b01631] |
Source(1):